BIRKERØD,
The customer is
The implementation has followed a process of pilot use of the suPARnostic® TurbiLatex product in a large cohort of approx. 1,700 patients and the findings of the study will be published shortly. The Hospital, however, has decided to implement suPARnostic® TurbiLatex immediately to broadly improve triage in the emergency department. The hospital has therefor submitted the first order to ViroGates.
Unrelated to the above, a Swedish provider of health tests, has decided to incorporate suPARnostic® Quick Triage in the standard panel of offerings to its corporate health test clients. The customer offers a range of health tests based on physiological and biological parameters to its clients in
Furthermore we, also today, received the first order from a customer from a different segment – the corporate health screening market. This is a new market that has seen the benefits of measuring the inflammation levels of workers in larger organisations in
The announcement can be found at https://www.virogates.com/investor/announcements
For further information please contact:
CEO,
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About
The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker measured by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments.
Disclaimer
Prospects about the future reflect
Contacts
Jakob Knudsen , CEO, +45 2226 1355, jk@virogates.com
Attachments
- 20201124-
ViroGates Company announcement 24.pdf
© Ritzau Denmark, source